NCT07244926尚未招募2 期
Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in Second-line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Without Actionable Gene Alterations: a Single-arm, Phase II Trial
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2025年12月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 31
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
In this single-arm, phase II study, we aimed to evaluate the efficacy and safety of sac-TMT plus bevacizumab in patients with advanced non-squamous NSCLC who showed disease progression on or after first-line ICI plus platinum-based chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years old, regardless of gender
- •Histologically or cytologically confirmed locally advanced or metastatic non-squamous NSCLC (stage IIIB/C or IV not amenable to curative treatment)
- •Negative for EGFR sensitizing mutations [no exon 19 deletion (19-Del) or exon 21 point mutation (L858R mutation)] and ALK fusion gene, and no known actionable gene alterations in ROS1, NTRK, BRAF, MET, KRAS, HER2, or RET.
- •Disease progression after first-line platinum-based chemotherapy combined with anti-PD-(L)1 therapy.
- •At least one measurable lesion according to RECIST v1.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 within 7 days prior to administration.
- •Expected life expectancy ≥ 12 weeks.
- •Adequate organ and bone marrow function.
- •Agreement to use effective medical contraception methods from the time of signing the informed consent form until 6 months after the last dose for female subjects of childbearing potential and male subjects with partners of childbearing potential.
- •Join the study voluntarily, signs the informed consent form, and is able to comply with the visits and related procedures stipulated in the protocol.
排除标准
- •Histologically or cytologically confirmed squamous cell NSCLC or mixed with small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma components.
- •Previously received any of the following treatments (including in the adjuvant or neoadjuvant setting): a) Therapy targeting TROP
- •b) Any drug therapy containing a topoisomerase I inhibitor, including Antibody-Drug Conjugate (ADC) therapy. c) Anti-angiogenic agents.
- •Requirement for strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4) within 2 weeks prior to the first dose or during the study period.
- •Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or history of corneal disease that prevents/delays corneal healing.
- •Known leptomeningeal metastasis, brainstem metastasis, spinal cord metastasis and/or compression, or active central nervous system (CNS) metastases. Subjects with brain metastases previously treated with local therapy can participate if they are clinically stable for at least 4 weeks prior to dosing and do not require corticosteroids or anticonvulsants for at least 14 days; subjects with untreated asymptomatic brain metastases may be enrolled after investigator assessment.
- •History of other malignancies within 3 years prior to dosing (except for tumors cured with local therapy, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, etc.).
- •Presence of severe cardiovascular or cerebrovascular diseases or risk factors.
- •Uncontrolled systemic diseases, as judged by the investigator.
- •Urinalysis shows urine protein ≥ ++ and confirmed 24-hour urine protein quantification > 1.0 g.
- •History of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment, current ILD or non-infectious pneumonitis, or suspected ILD or non-infectious pneumonitis that cannot be ruled out by imaging at screening.
- •Clinically severe pulmonary impairment due to concurrent pulmonary diseases.
- •Subjects with active chronic inflammatory bowel disease, gastrointestinal obstruction, severe ulcer, gastrointestinal perforation, intra-abdominal abscess, or acute gastrointestinal bleeding.
- •Tumor invasion or compression of surrounding vital organs and blood vessels accompanied by related symptoms (e.g., superior vena cava syndrome), or risk of esophagotracheal fistula or esophagopleural fistula.
- •History of bleeding tendency or coagulation disorder and/or clinically significant bleeding symptoms or risks within 4 weeks prior to the first dose.
- •Use of aspirin (>325 mg/day) or treatment with dipyridamole or clopidogrel within 2 weeks prior to the first dose.
- •Use of full-dose oral or intravenous anticoagulants or thrombolytic agents within 2 weeks prior to the first dose.
- •Biopsy or other minor surgery (excluding placement of vascular access devices) within 7 days prior to the first dose.
- •Toxicity from previous anti-tumor therapy has not recovered to ≤ Grade 1 or the level specified in the eligibility criteria (except for toxicities judged by the investigator to pose low safety risks, such as alopecia, fatigue, etc.).
- •Known active tuberculosis. Subjects suspected of having active tuberculosis require clinical evaluation to exclude it.
- •History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- •Active Hepatitis B or Hepatitis C. Note: Subjects who are HBsAg positive are required to receive anti-hepatitis B virus therapy during the study treatment period.
- •Positive human immunodeficiency virus (HIV) test or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
- •Known allergy to the investigational drug or any of its components, history of severe hypersensitivity reactions to other biological agents.
- •Major surgery within 4 weeks prior to dosing or anticipated need for major surgery during the study period.
- •Severe infection within 4 weeks prior to dosing, active infection requiring systemic anti-infective therapy within 2 weeks prior to dosing.
- •Non-specific immunomodulatory therapy within 2 weeks prior to dosing.
- •Radiation therapy to lung lesions with a total dose > 30 Gy within 6 months prior to dosing; non-thoracic radiotherapy with a total dose > 30 Gy or extensive radiotherapy (including radionuclide therapy such as Strontium-89) within 4 weeks prior to dosing; palliative radiotherapy for symptom control is allowed but must be completed at least 2 weeks before the first dose.
- •Administration of live vaccines within 30 days prior to dosing, or planned administration of live vaccines during the study period.
- •Rapid deterioration of condition during the screening period prior to dosing.
- •Pregnant or lactating women.
- •Local or systemic diseases caused by non-malignant conditions, or diseases or symptoms secondary to the tumor, that could lead to high medical risk and/or uncertainty in survival assessment.
- •Any condition that, in the investigator's judgment, interferes with the evaluation of the investigational product, subject safety, or interpretation of study results, or any other situation where the investigator considers the subject unsuitable for participation in this study.
研究组 & 干预措施
Sac-TMT plus bevacizumab
Experimental
干预措施: Sacituzumab tirumotecan plus bevacizumab (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: up to approximately 60 months
ORR is defined as the proportion of patients with a confirmed complete (CR) or partial response (PR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the investigator.
次要结局
- Disease control response (DCR)(up to approximately 60 months)
- Duration of response (DOR)(Until progression or death, up to approximately 60 months)
- Progression-free survival (PFS)(Until progression or death, up to approximately 60 months)
- Overall Survival (OS)(Until death, up to approximately 60 months.)
- Incidence and severity of adverse events (AEs)(up to approximately 60 months)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain MetastasisLung CancerNCT07197008Li-kun Chen50
尚未招募
2 期
Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract CancerNCT07129018Union Hospital, Tongji Medical College, Huazhong University of Science and Technology63
尚未招募
2 期
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBCNCT07244874Tianjin Medical University Cancer Institute and Hospital41
尚未招募
2 期
TAS-102 plus Bevacizumab combination as salvage therapy in elderly patients with metastatic colorectal cancer, phase 2 trialmetastatic colorectal cancerJPRN-UMIN000021664Tokushima University Hospital25
进行中（未招募）
1 期
Phase II study with cetuximab, irinotecan and sunitinib (CIS) for patients with treatment resistant colorectal cancerEUCTR2007-004232-22-DKOdense University Hospital